1.北京中医药大学,北京市朝阳区北三环东路11号,100029
2.中国中医科学院西苑医院
fanmr1974@qq.com
收稿:2022-11-08,
修回:2023-03-22,
纸质出版:2023-12-17
移动端阅览
赵晓利,梁艳霞,苏文文等.复元蠲痹法治疗结缔组织病相关间质性肺病[J].中医杂志,2023,64(24):2579-2583.
ZHAO Xiaoli,LIANG Yanxia,SU Wenwen,et al.Treatment of Connective Tissue Diseases-associated Interstitial Lung Disease by the Origin-restoring and Bi (痹)-alleviating Method[J].Journal of Traditional Chinese Medicine,2023,64(24):2579-2583.
赵晓利,梁艳霞,苏文文等.复元蠲痹法治疗结缔组织病相关间质性肺病[J].中医杂志,2023,64(24):2579-2583. DOI: 10.13288/j.11-2166/r.2023.24.015.
ZHAO Xiaoli,LIANG Yanxia,SU Wenwen,et al.Treatment of Connective Tissue Diseases-associated Interstitial Lung Disease by the Origin-restoring and Bi (痹)-alleviating Method[J].Journal of Traditional Chinese Medicine,2023,64(24):2579-2583. DOI: 10.13288/j.11-2166/r.2023.24.015.
认为结缔组织病相关间质性肺病(CTD-ILD)以肾精亏虚为根本病机,肺络痹阻贯穿疾病始终,环境毒邪为CTD-ILD发生发展的重要诱因。提出以复元蠲痹法治疗CTD-ILD,复元即补益肺、脾、肾以培本固元,以二仙汤合六君子汤加减;蠲痹即采用祛风通络或除癥通络之法以恢复肺络通畅之性,常用穿山龙-地龙、醋三棱-醋莪术对药及藤类药,同时注重对环境毒邪的祛除以促正气恢复。
It is believed that the fundamental pathogenesis of the connective tissue diseases-associated interstitial lung disease (CTD-ILD) is kidney essence deficiency, with lung collateral obstruction throughout the disease, and environmental toxin pathogen is the important causative factors for the development of CTD-ILD. This article proposed to restore origin and alleviate
bi
(痹) for CTD-ILD, for which restoring origin means tonifying the lungs, spleen and kidneys to bank up the roots and consolidate the original
qi
, with modified
Erxian Decoction
(二仙汤) plus
Liu Junzi Decoction
(六君子汤); alleviating
bi
means expelling wind and dredging collaterals, and eliminating the mass to restore the smoothness of the lung collaterals, with paired medicines of Chuanshanlong (
Dioscorea nipponica
)-Dilong (
Kalanchoe pinnata
), Vinegar-processed Sanleng (
Sparganium stoloniferum
)-Vinegar-processed Ezhu (
Curcuma zedoaria
), and stem-type medicines, and emphasized on removing the environmental toxin pathogens to facilitate the recovery of healthy
qi
.
KONDOH Y , MAKINO S , OGURA T , et al . 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease [J]. Respir Investig , 2021 , 59 ( 6 ): 709 - 740 .
CHUNG JH , COX CW , MONTNER SM , et al . CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis [J]. AJR Am J Roentgenol , 2018 , 210 ( 2 ): 307 - 313 .
MATHAI SC , DANOFF SK . Management of interstitial lung disease associated with connective tissue disease [J]. BMJ , 2016 , 352 : h6819 . doi: 10.1136/bmj.h6819 http://dx.doi.org/10.1136/bmj.h6819 .
JEE AS , CORTE TJ . Current and emerging drug therapies for connective tissue disease-interstitial lung disease (CTD-ILD) [J]. Drugs , 2019 , 79 ( 14 ): 1511 - 1528 .
梁艳霞 , 樊茂蓉 , 王冰 , 等 . 结缔组织病相关间质性肺病中医病因病机及治疗研究进展 [J]. 中国医药导报 , 2022 , 19 ( 15 ): 33 - 36 .
CERRO CHIANG G , PARIMON T . Understanding interstitial lung diseases associated with connective tissue disease (CTD-ILD): genetics, cellular pathophysiology,and biologic drivers [J]. Int J Mol Sci , 2023 , 24 ( 3 ): 2405 .
吴以岭 . 络病病机探析 [J]. 中医杂志 , 2005 , 46 ( 4 ): 243 - 245 .
姜良铎 , 秦英 , 杨君 , 等 . 试论“环境毒” [J]. 中国中医基础医学杂志 , 1999 , 5 ( 9 ): 5 - 7,69 .
郑洪新 . 中医病因新说:环境毒邪 [J]. 辽宁中医杂志 , 2002 , 29 ( 2 ): 63 - 64 .
SHAO T , SHI X , YANG S , et al . Interstitial lung disease in connective tissue disease: a common lesion with hete-rogeneous mechanisms and treatment considerations [J]. Front Immunol , 2021 , 12 : 684699 . doi: 10.3389/fimmu. 2021.684699 http://dx.doi.org/10.3389/fimmu.2021.684699 .
CHEN HH , YONG YM , LIN CH , et al . Air pollutants and development of interstitial lung disease in patients with connective tissue disease: a population-based case-control study in Taiwan [J]. BMJ Open , 2020 , 10 ( 12 ): e041405 . doi: 10.1136/bmjopen-2020-041405 http://dx.doi.org/10.1136/bmjopen-2020-041405 .
SACK C , VEDAL S , SHEPPARD L , et al . Air pollution and subclinical interstitial lung disease: the multi-ethnic study of atherosclerosis (MESA) air-lung study [J]. Eur Respir J , 2017 , 50 ( 6 ): 1700559 . doi: 10.1183/13993003. 00559-2017 http://dx.doi.org/10.1183/13993003.00559-2017 .
MARGARITOPOULOS GA , HARARI S , CAMINATI A , et al . Smoking-related idiopathic interstitial pneumonia: a review [J]. Respirology , 2016 , 21 ( 1 ): 57 - 64 .
安云霞 , 张晓菊 , 汪铮 , 等 . 淫羊藿苷对肺纤维化大鼠模型的影响及其机制 [J]. 安徽医科大学学报 , 2020 , 55 ( 12 ): 1840 - 1844 .
尹佳 , 刘会会 , 强明敏 , 等 . 仙茅的药理作用研究进展 [J]. 中国当代医药 , 2021 , 28 ( 25 ): 32 - 36 .
李博 , 耿刚 . 黄芪的化学成分与药理作用研究进展 [J]. 中西医结合研究 , 2022 , 14 ( 4 ): 262 - 264 .
栾智华 , 张东坡 , 刘必旺 , 等 . 黄芪甲苷对肺纤维化小鼠VEGF/VEGFR2信号通路的影响 [J]. 时珍国医国药 , 2019 , 30 ( 7 ): 1611 - 1613 .
李媛媛 , 周鸿铭 . 穿山龙总皂苷的药理作用及机制研究进展 [J]. 中医药学报 , 2020 , 48 ( 5 ): 73 - 77 .
吴晓东 , 徐胜梅 , 杨智华 , 等 . 穿山龙总皂苷通过TGF-β/Smad信号通路减轻类风湿关节炎相关间质性肺病的肺纤维化 [J]. 中华中医药学刊 , 2023 , 41 ( 1 ):99-102, 281 - 283 .
商烨 , 齐丽娜 , 金华 , 等 . 地龙化学成分及药理活性研究进展 [J]. 药物评价研究 , 2022 , 45 ( 5 ): 989 - 996 .
刘翀羽 . 藤类药的应用研究 [J]. 山西中医 , 2015 , 31 ( 7 ): 59 - 60 .
黄礼闯 , 赵梦亭 , 桑夏楠 , 等 . 三棱-莪术药对化学成分及药理作用研究进展 [J]. 中华中医药杂志 , 2021 , 36 ( 11 ): 6612 - 6616 .
PASQUALE MK , XU Y , BAKER CL , et al . COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members [J]. Int J Chron Obstruct Pulmon Dis , 2016 , 11 : 111 - 121 . doi: 10.2147/COPD.S94323 http://dx.doi.org/10.2147/COPD.S94323 .
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories . ATS statement: guidelines for the six-minute walk test [J]. Am J Respir Crit Care Med , 2002 , 166 ( 1 ): 111 - 117 .
0
浏览量
3
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号